Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MNC for Single Right Ventricle Failure
NCT02549625Phase 1Completed
- Start
- Aug 2015
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in congenital heart disease (CHD) and heart failure (HF). Primary endpoint: Number of related serious adverse events at 6 months. Started Aug 2015; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
congenital heart disease (CHD)heart failure (HF)
Beyond the preview
Go deeper on NCT02549625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549625.